Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha interferons: a clinical overview.

R J Spiegel1

  • 1Department of Oncology, Schering-Plough Corporation, Kenilworth, New Jersey.

Urology
|October 1, 1989
PubMed
Summary
This summary is machine-generated.

Alpha interferons, used in over 5,000 patients, offer insights into biological drug development. Key findings include dose-response relationships, schedule dependence, and toxicity profiles for anticancer and antiviral therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technical assessment of fuel cell operation on anaerobic digester gas at the Yonkers, NY, wastewater treatment plant.

Waste management (New York, N.Y.)·2003
Same author

Biologic therapy of cancer.

New Jersey medicine : the journal of the Medical Society of New Jersey·1990
Same author

Alpha interferons: 1989.

Cancer investigation·1990
Same author

Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.

Journal of interferon research·1989
Same author

Comparison of finite-difference time-domain SAR calculations with measurements in a heterogeneous model of man.

IEEE transactions on bio-medical engineering·1989
Same author

Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia.

Journal of the National Cancer Institute·1989
Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026
Same journal

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026
Same journal

Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.

Urology·2026
Same journal

Intractable Epistaxis and Severe Hypertension in a Young Woman.

Urology·2026
Same journal

A 53-Year-Old Man with Elevated PSA and a Cystic Pelvic Lesion.

Urology·2026
Same journal

Low-Grade, Papillary Bladder Tumors A plea for in-office fulguration.

Urology·2026
See all related articles

Area of Science:

  • Biologics and Biotechnology
  • Pharmacology
  • Oncology and Virology

Background:

  • Recombinant alpha interferons serve as a model for biological drug clinical development.
  • Extensive patient data (over 5,000) have informed general principles for phase I-III testing of biologics.

Purpose of the Study:

  • To review existing safety and efficacy data for alpha interferons.
  • To summarize key findings from clinical trials regarding biological compound development.

Main Methods:

  • Analysis of data from over 5,000 patients treated with alpha interferons.
  • Review of clinical trial results focusing on dose-response, schedule dependence, and toxicity.

Main Results:

  • Clinical trials suggest dose-response relationships and schedule dependence for alpha interferons.

Related Experiment Videos

  • Tumor burden and patient subtypes are critical factors for biological compound activity.
  • Alpha interferons show promise in treating chronic viral hepatitis, indicating an antiviral role.
  • Common toxicities include dose-limiting fever/influenza-like symptoms; CNS, hematologic, and GI toxicities are generally mild and manageable.
  • Cardiovascular toxicity concerns have not been substantiated in larger trials.

    • Conclusions:

    • Alpha interferons provide a prototype for biological drug development, with established safety and efficacy profiles.
    • Further research will clarify the definitive roles of alpha interferons in antineoplastic and antiviral treatments.